A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and TSR-042 in Patients With Platinum Resistant Ovarian Cancer
Condition: Platinum-resistant Ovarian Cancer Interventions: Drug: Niraparib; Drug: TSR-042 Sponsors: Tesaro, Inc.; Gynecologic Oncology Group Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials